Q: Why are TB-500 and BPC-157 combined?
A: The peptides have been studied for different biological processes related to tissue response and recovery. Combining them provides both peptides within one formulation, but there is not sufficient clinical evidence to conclude that the combination produces better healing or recovery outcomes.
Q: What is TB-500?
A: TB-500 generally refers to a synthetic fragment related to thymosin beta-4. Research interest has focused on biological processes associated with tissue response and wound healing, but FDA has noted a lack of human exposure data for TB-500 drug products.
Q: What is BPC-157?
A: BPC-157 is a synthetic peptide that has been studied primarily in laboratory and animal research. Research has explored potential effects involving tissue repair and inflammatory pathways, but human safety and effectiveness have not been established.
Q: Will TB-500 / BPC-157 speed up injury recovery?
A: That outcome cannot be guaranteed or considered established. Research has generated interest in both peptides for recovery-related processes, but there is not sufficient human clinical evidence to establish that this treatment accelerates recovery from an injury.
Q: Is this an anti-inflammatory treatment?
A: Research has explored BPC-157 and related peptides in inflammatory pathways, but this combination is not an FDA-approved treatment for inflammatory conditions and should not be considered a proven anti-inflammatory therapy.
Q: Are there safety considerations with these peptides?
A: Yes. Human safety information is limited. FDA has identified potential concerns involving immunogenicity, peptide-related impurities, and characterization of these substances. Our healthcare provider should review the potential risks, available evidence, and your individual health information before treatment is considered.
